Skip to main content
Full access
Features
Published Online: 31 October 2014

Delirium and Hypovitaminosis D: Neuroimaging Findings

Publication: The Journal of Neuropsychiatry and Clinical Neurosciences

Abstract

The authors examined the frequency of neuroimaging findings of cortical atrophy and/or cerebrovascular disease in patients with delirium with hypovitaminosis D and normal vitamin D levels. Of 32 patients with delirium with hypovitaminosis D who were neuroimaged, 91.4% had neuroimaging findings, despite only five cases having a comorbid diagnosis of dementia. Similar frequencies of cortical atrophy and/or cerebrovascular disease were found in patients with delirium with normal vitamin D levels. Further research with a larger sample size is needed to compare neuroimaging findings between normal patients and patients with hypovitaminosis D with delirium.
Premorbid cognitive impairment is a risk factor for delirium. Because vitamin D deficiency has been associated with cognitive impairment, hypovitaminosis D may be a plausible relative risk factor for the development of delirium.1,2 In animal and human studies, vitamin D, a secosteroid hormone in its active metabolite form that binds to vitamin D receptors, has been linked to numerous cerebral processes including neuroprotection.3 Masoumi et al.4 demonstrated that 1,25-dihydroxyvitamin D (the active form of vitamin D) strongly stimulated β-amyloid phagocytosis and subsequent clearance providing protection against cellular apoptosis, known to be important in the pathogenesis of Alzheimer's disease. Vitamin D promotes neuroprotection by modulating the production of choline acetyltransferase, the key enzyme in the biosynthesis of acetylcholine.5 Because cholinergic deficits are implicated in delirium, hypovitaminosis D has been speculated to play a role in developing delirium.1,6
Vitamin D has been experimentally linked to both antineurodegenerative and anti-ischemic effects. Ischemic infarcts and white matter hyperintensities have been associated with hypovitaminosis D.7 Using data from the Nutrition, Aging, and Memory in Elders study,8 Buell et al.9 found an inverse association between vitamin D levels and the presence of white matter hyperintensities and large vessel infarcts. Vitamin D levels were also found to be inversely associated with neuroimaging evidence of multiple sclerosis activity.10 A review by Annweiler et al.11 revealed reports of ischemic infarcts and white matter hypertintensities in hypovitaminosis D. This, combined with the reported findings of executive dysfunction in hypovitaminosis D, led to their proposal that hypovitaminosis D may be associated with dysfunction of frontal-subcortical circuits,11 which may be of significance in delirium. Despite the theoretical basis for a link between vitamin D and delirium, to date there has been only a limited exploration of this association.12 We explored the frequency of cortical atrophy and/or cerebrovascular disease in patients with delirium with hypovitaminosis D and those with normal range vitamin D levels.

Methods

We conducted a retrospective cross-sectional study of inpatients at three academic medical centers in Hamilton, Ontario, Canada, by extracting electronic data systematically from medical records, which used ICD-10.13 This study was approved by McMaster University's institutional ethics review board. Eligible cases were defined as any medical or surgical inpatient 18 years of age or older who received a discharge diagnosis of delirium between January 1, 2011 and July 31, 2012, who had a serum 25-hydroxyvitamin D test and had neuroimaging performed. Serum total calcium, magnesium, phosphate, and intact parathyroid hormone values were also extracted. Local laboratory reference values were used for suboptimal vitamin D (or hypovitaminosis D), defined as a 25-hydroxyvitamin D level < 75 nmol/L, and optimal (or sufficient) vitamin D, defined as a 25-hydroxyvitamin D level ≥ 75 nmol/L. Diagnoses of dementia for these cases were also extracted from the database. Neuroimaging findings were classified as (1) vascular disease consisting of micro- and macro-angiopathic changes, (2) cortical atrophy, or (3) mixed, with vascular disease and cortical atrophy. Analyses compared subjects with hypovitaminosis D to those with sufficient vitamin D levels and associated neuroimaging findings. Descriptive analyses generating means and standard error of the mean for continuous data and proportions for categorical data were conducted. Statistical analyses were performed using SAS version 9.2 (SAS Institute, Cary, NC), and p<0.05 was the level of significance.

Results

Table 1 contains demographic and laboratory characteristics of the study group. A total of 51 of 1232 patients with delirium had all the characteristics and were included in the study. Of those, 35 patients (68.6%) showed hypovitaminosis D, and 16 showed sufficient vitamin D levels. Mean age was 78.5±1.8 years. In the hypovitaminosis D group, cerebral vasculopathy and/or atrophy on neuroimaging was found in 32 patients: eight patients with vascular disease, seven patients with cortical atrophy, and 17 patients with cortical atrophy plus vascular disease, whereas the sufficient vitamin D group (N=13) included four patients with vascular disease, one patient with cortical atrophy, and eight patients with cortical atrophy plus vascular disease. A total of six patients (three patients in each comparison group) had either no CT scan findings or other CT scan findings. A comorbid dementia diagnosis was found in five of 32 (15.6%) patients with hypovitaminosis D and three of 13 (23.1%) in those with sufficient vitamin D (Table 1). The differences in frequency of CT scan abnormalities and frequency of dementia diagnosis were not significant between the hypovitaminosis D and normal range vitamin D groups. There were no significant differences in vitamin D levels found by category (i.e., vascular, atrophy, or mixed) of head CT scan findings. Analysis of covariance (ANCOVA) revealed higher levels of serum total calcium in the atrophy neuroimaging group compared with either vascular or mixed groups while controlling for age, which was a finding of uncertain significance.
TABLE 1. Population Characteristics and Comparison of Means (Standard Error of the Mean) Across Vitamin D Subgroups (N=45 for All Characteristics Examined)
Variable25-Hydroxyvitamin D Level <75 (N=32)25-Hydroxyvitamin D Level ≥75 (N=13)Pr>F
Age (years)77.0±2.382±2.5Not significant
Sex (% male)66230.01a
25-Hydroxyvitamin D level (≥75 nmol/L)48.0±2.8101.7±8.9<0.0001
 ANCOVA (age)<0.0001
Total calcium (2.15–2.55 mmol/L)2.22±0.032.22±0.06Not significant
 ANCOVA (age)Not significant
Magnesium (0.66–1.07 mmol/L)0.76±0.030.79±0.04Not significant
 ANCOVA (age)Not significant
Phosphate (0.80–1.45 mmol/L)0.97±0.050.92±0.04Not significant
 ANCOVA (age)Not significant
Percent dementia15.623.1Not significant
CT imaging results   
 Percent vascular2531Not significant
 Percent atrophy228Not significant
 Percent mixed vascular/atrophy5361Not significant
a
Mantel-Haenszel chi-square is reported.

Discussion

More than 90% of patients with delirium with hypovitaminosis D exhibited neuroanatomic vascular and/or cortical atrophy abnormality on CT scan findings in this retrospective sample. The frequency of these neuroimaging findings in patients with delirium with hypovitaminosis D was not significantly different from those of patients with delirium with a normal range vitamin D.
Numerous brain dysfunctions have been linked to vitamin D deficits and/or dysfunction of its vitamin D receptor,3 although causality has not yet been determined. Because the role of vitamin D on brain function has become more explicit, clinicians and researchers have speculated that hypovitaminosis D may play an important role in the pathogenesis of neurocognitive dysfunction.14 However, a recent study found no association between hypovitaminosis D and cognitive function as represented by Mini-Mental State Examination scores.15
Notably, the majority of patients with hypovitaminosis D who had head CT scans (N=32; 91.4%) showed cerebrovascular and/or cortical atrophy abnormalities, but only five of 32 (15.6%) of those included in the sample had a comorbidly diagnosed dementia, suggesting that many delirium cases with positive CT scans do not have a formal dementia diagnosis established before the delirium episode. The finding of 91.4% of delirium cases with hypovitaminosis D and abnormal cortical atrophy and/or cerebrovascular findings is striking and suggests that such CT scan findings may correlate with a tendency toward “delirium proneness” not necessarily requiring clinical cognitive impairment sufficient to render a clinical diagnosis of dementia separate from the delirium diagnosis. Whether there is possibility of predementia mild cognitive impariment requires further investigation. Despite previously reported studies of ischemic and white matter changes in the brains of individuals with hypovitaminosis D,7,11 in our study population, there was no effect of vitamin D status on any type of vascular and/or cortical CT scan abnormality, thus failing to demonstrate an effect of vitamin D status per se on these findings.
This study is limited by the relatively small sample size in both the normal and hypovitamin D groups and hence had a limited power to detect neuroimaging and vitamin D status differences. Furthermore, all factors known to contribute to hypovitaminosis D could not be included in our model due to the availability of information in our data repository (e.g., environmental factors, nutritional status, race, hemodynamics, medications and supplements, and restricted hospital settings). Further neuroimaging studies are therefore needed to determine whether hypovitaminosis D and neurodegenerative and/or cerebrovascular lesions may contribute to delirium.
This was a naturalistic, retrospective study accomplished based on data generated from delirium cases managed in academic medical centers. At these centers, there is no standardized order set or common clinical pathway for the medical management of delirium. Some physicians caring for delirium patients at these medical centers order studies of calcium, phosphorus, and vitamin D based on the clinical presentation of the delirium patients in search of modifiable variables. Because we studied only those delirium patients with data about vitamin D status, we cannot systematically compare those cases who had these studies obtained to the other delirium cases on whom such studies were not obtained. Ideally, in a larger study with a prospective design, one would seek to standardize laboratory assessments to avoid possibly confounders that may obscure results.
Classification of CT scan results as vascular disease, atrophy, and mixed vascular/atrophy were made on the basis of routine neuroradiology interpretation. Our data were extracted directly from the neuroradiological reports and presented as seen in Table 1. As such, it is not possible to a priori establish parameters for interrater reliability, standardization of imaging protocols, and other aspects of the neuroimaging methodology, which would be clearly desirable in a prospective design wherein such technical details could perhaps be more rigorously standardized, thus minimizing the possibility of sources of interrater error.

Conclusions

Structural neuroimaging abnormalities were found in 91.4% of a sample of patients with hypovitaminosis D and delirium. A similar high frequency of CT scan abnormalities was found in patients with delirium with normal vitamin D status. Vitamin D status may be a modifiable risk factor for the development of delirium, but larger studies may be needed to fully elaborate any such association. Clinicians treating patients with delirium may consider assessing vitamin D status and vitamin D supplementation. The mechanism by which hypovitamnosis D is associated with neuroimaging findings in delirium remains to be elucidated.

References

1.
Leentjens AFG, van der Mast RC: Delirium in elderly people: an update. Curr Opin Psychiatry 2005; 18:325–330
2.
Annweiler C, Allali G, Allain P, et al: Vitamin D and cognitive performance in adults: a systematic review. Eur J Neurol 2009; 16:1083–1089
3.
Kalueff AV, Tuohimaa P: Neurosteroid hormone vitamin D and its utility in clinical nutrition. Curr Opin Clin Nutr Metab Care 2007; 10:12–19
4.
Masoumi A, Goldenson B, Ghirmai S, et al: 1alpha,25-dihydroxyvitamin D3 interacts with curcuminoids to stimulate amyloid-beta clearance by macrophages of Alzheimer’s disease patients. J Alzheimers Dis 2009; 17:703–717
5.
Sonnenberg J, Luine VN, Krey LC, et al: 1,25-Dihydroxyvitamin D3 treatment results in increased choline acetyltransferase activity in specific brain nuclei. Endocrinology 1986; 118:1433–1439
6.
Hshieh TT, Fong TG, Marcantonio ER, et al: Cholinergic deficiency hypothesis in delirium: a synthesis of current evidence. J Gerontol A Biol Sci Med Sci 2008; 63:764–772
7.
Buell JS, Tucker KL: The value of physiologic vitamin D as a biomarker of dementia. Drugs Today (Barc) 2011; 47:223–231
8.
Scott TM, Peter I, Tucker KL, et al: The Nutrition, Aging, and Memory in Elders (NAME) study: design and methods for a study of micronutrients and cognitive function in a homebound elderly population. Int J Geriatr Psychiatry 2006; 21:519–528
9.
Buell JS, Dawson-Hughes B, Scott TM, et al: 25-Hydroxyvitamin D, dementia, and cerebrovascular pathology in elders receiving home services. Neurology 2010; 74:18–26
10.
Mowry EM, Waubant E, McCulloch CE, et al: Vitamin D status predicts new brain magnetic resonance imaging activity in multiple sclerosis. Ann Neurol 2012; 72:234–240
11.
Annweiler C, Montero-Odasso M, Muir SW, et al: Vitamin D and brain imaging in the elderly: should we expect some lesions specifically related to hypovitaminosis D? Open Neuroimaging J 2012; 6:16–18
12.
Morandi A, Barnett N, Miller RR, et al: Vitamin D and delirium in critically ill patients: a preliminary investigation. J Crit Care 2012;28:230–235
13.
World Health Organization: The ICD-10 Classification of Mental and Behavioural Disorders: Clinical Descriptions and Diagnostic Guidelines. Geneva, World Health Organization, 1992
14.
Buell JS, Dawson-Hughes B: Vitamin D and neurocognitive dysfunction: preventing “D”ecline? Mol Aspects Med 2008; 29:415–422
15.
Leedahl DD, Cunningham JL, Drake MT, et al: Hypovitaminosis D in psychiatric inpatients: clinical correlation with depressive symptoms, cognitive impairment, and prescribing practices. Psychosomatics 2013; 54:257–262

Information & Authors

Information

Published In

Go to The Journal of Neuropsychiatry and Clinical Neurosciences
Go to The Journal of Neuropsychiatry and Clinical Neurosciences
The Journal of Neuropsychiatry and Clinical Neurosciences
Pages: 69 - 71
PubMed: 25111282

History

Received: 4 June 2013
Accepted: 6 January 2014
Published ahead of print: 31 October 2014
Published in print: Winter 2015
Published online: 26 February 2015

Authors

Affiliations

James A. Bourgeois, O.D., M.D.
From the Dept. of Psychiatry/Langley Porter Psychiatric Institute, Consultation-Liaison Service, University of California San Francisco Medical Center, San Francisco, CA (JAB); Dept. of Psychiatry and Behavioural Neurosciences, Michael G. DeGroote School of Medicine, Faculty of Health Sciences, McMaster University, Hamilton, Ontario, Canada (AH, JF); St. Joseph’s Healthcare Hamilton, West 5th Campus, Hamilton, Ontario, Canada (AH, DKT); and Dept. of Psychiatry and Behavioral Sciences, University of California, Davis, CA (GLX)
Ana Hategan, M.D.
From the Dept. of Psychiatry/Langley Porter Psychiatric Institute, Consultation-Liaison Service, University of California San Francisco Medical Center, San Francisco, CA (JAB); Dept. of Psychiatry and Behavioural Neurosciences, Michael G. DeGroote School of Medicine, Faculty of Health Sciences, McMaster University, Hamilton, Ontario, Canada (AH, JF); St. Joseph’s Healthcare Hamilton, West 5th Campus, Hamilton, Ontario, Canada (AH, DKT); and Dept. of Psychiatry and Behavioral Sciences, University of California, Davis, CA (GLX)
Jennifer Ford, M.S.L.P., M.D.
From the Dept. of Psychiatry/Langley Porter Psychiatric Institute, Consultation-Liaison Service, University of California San Francisco Medical Center, San Francisco, CA (JAB); Dept. of Psychiatry and Behavioural Neurosciences, Michael G. DeGroote School of Medicine, Faculty of Health Sciences, McMaster University, Hamilton, Ontario, Canada (AH, JF); St. Joseph’s Healthcare Hamilton, West 5th Campus, Hamilton, Ontario, Canada (AH, DKT); and Dept. of Psychiatry and Behavioral Sciences, University of California, Davis, CA (GLX)
Daniel K. Tisi, R.D., M.Sc.
From the Dept. of Psychiatry/Langley Porter Psychiatric Institute, Consultation-Liaison Service, University of California San Francisco Medical Center, San Francisco, CA (JAB); Dept. of Psychiatry and Behavioural Neurosciences, Michael G. DeGroote School of Medicine, Faculty of Health Sciences, McMaster University, Hamilton, Ontario, Canada (AH, JF); St. Joseph’s Healthcare Hamilton, West 5th Campus, Hamilton, Ontario, Canada (AH, DKT); and Dept. of Psychiatry and Behavioral Sciences, University of California, Davis, CA (GLX)
Glen L. Xiong, M.D.
From the Dept. of Psychiatry/Langley Porter Psychiatric Institute, Consultation-Liaison Service, University of California San Francisco Medical Center, San Francisco, CA (JAB); Dept. of Psychiatry and Behavioural Neurosciences, Michael G. DeGroote School of Medicine, Faculty of Health Sciences, McMaster University, Hamilton, Ontario, Canada (AH, JF); St. Joseph’s Healthcare Hamilton, West 5th Campus, Hamilton, Ontario, Canada (AH, DKT); and Dept. of Psychiatry and Behavioral Sciences, University of California, Davis, CA (GLX)

Notes

Send correspondence to James A. Bourgeois, O.D., M.D.; e-mail: [email protected]

Metrics & Citations

Metrics

Citations

Export Citations

If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Simply select your manager software from the list below and click Download.

For more information or tips please see 'Downloading to a citation manager' in the Help menu.

Format
Citation style
Style
Copy to clipboard

There are no citations for this item

View Options

View options

PDF/ePub

View PDF/ePub

Get Access

Login options

Already a subscriber? Access your subscription through your login credentials or your institution for full access to this article.

Personal login Institutional Login Open Athens login
Purchase Options

Purchase this article to access the full text.

PPV Articles - Journal of Neuropsychiatry and Clinical Neurosciences

PPV Articles - Journal of Neuropsychiatry and Clinical Neurosciences

Not a subscriber?

Subscribe Now / Learn More

PsychiatryOnline subscription options offer access to the DSM-5-TR® library, books, journals, CME, and patient resources. This all-in-one virtual library provides psychiatrists and mental health professionals with key resources for diagnosis, treatment, research, and professional development.

Need more help? PsychiatryOnline Customer Service may be reached by emailing [email protected] or by calling 800-368-5777 (in the U.S.) or 703-907-7322 (outside the U.S.).

Media

Figures

Other

Tables

Share

Share

Share article link

Share